Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Unmodified phosphodiester oligodeoxynucleotides (PO-oligos) are rapidly degraded by nucleases, limiting their use as antisense therapeutics.
• Phosphorothioate oligonucleotides (PS-oligos) offer enhanced stability but are slowly hydrolyzed by plasma enzymes, primarily from the 3 -end.

Purpose of the Study:

• To identify the specific human plasma enzyme responsible for the degradation of phosphorothioate oligonucleotides (PS-oligos).
• To investigate potential inhibitors of this enzymatic degradation pathway.

Main Methods:

• Enzyme assays using plasma samples.
• Identification of the responsible enzyme through biochemical characterization.
• Testing of adenosine or deoxyadenosine (alpha-thio)triphosphates as inhibitors.

Main Results:

• The human plasma 3 -exonuclease responsible for PS-oligo degradation was identified as a soluble form of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1).
• NPP1 is also known as the plasma cell differentiation antigen PC-1.
• Adenosine or deoxyadenosine (alpha-thio)triphosphates were found to be potent inhibitors of NPPs.

Conclusions:

• NPP1 is the key enzyme mediating the degradation of PS-oligos in human plasma.
• Understanding this degradation pathway and identifying inhibitors like adenosine or deoxyadenosine (alpha-thio)triphosphates could lead to improved antisense oligonucleotide therapies.